Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the skin changes that can occur with hormonal contraceptive use and highlights various mechanisms and potential treatment strategies but reports no new clinical results.

Hormonal contraceptives and therapies regulate organ functions and treat various conditions.

This study found that cyproterone acetate with ethynyl estradiol improved acne and seborrhea within 3–6 months in women, but had less satisfactory results for alopecia and hirsutism.

This review discusses the role of hormonal influences and antiandrogenic treatments in managing hirsutism and other androgenic manifestations in women, highlighting cyproterone acetate as a beneficial option for cosmetically sensitive patients, and reports no new clinical results.

This review discusses the role of antiandrogenic gestagens in treating androgen-dependent skin disorders and highlights the need for dermatologists to collaborate with endocrinologists and gynecologists for effective management.

This article reviews hair loss associated with oral contraceptive use and suggests that while diffuse effluvium is usually harmless, androgenetic alopecia caused by certain contraceptive types requires a change in medication; no new clinical results are reported.

This review discusses the favorable effects of anti-androgens in treating severe skin conditions like acne, seborrhoea, androgenic alopecia, and hirsutism but reports no new clinical results, emphasizing the importance of understanding side effects and hormone interactions.

This article suggests using oral contraceptives with antiandrogenic properties for women with virilization symptoms like acne and advises higher doses of antiandrogens for severe acne, androgenic alopecia, or idiopathic hirsutism.

This article reviews pathologic mechanisms causing hair changes in women on hormonal contraceptives or pregnant and reports no new study results; hormonal effects on the hair cycle stages are suggested.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.

This study concluded that combined hormonal contraceptives containing desogestrel, drospirenone, or cyproterone acetate were associated with a higher risk of venous thromboembolism compared to those containing levonorgestrel.

This review discusses the increased risk of venous thromboembolism associated with combined hormonal contraceptives, particularly noting higher risks with certain progestins like desogestrel, gestodene, and cyproterone acetate, but reports no new clinical findings.

This article reviews the negative effects of androgenic disorders and highlights that newer oral contraceptives with less androgenic progestins may reduce these effects and improve compliance, but it reports no new results.

This study reports that among young women, combined oral contraceptives containing chlormadinone, among others, are associated with an increased risk of venous thromboembolism compared to those containing levonorgestrel with low ethinylestradiol.

This article discusses the mechanisms and therapeutic use of antiandrogens, specifically cyproterone acetate and chlormadinone acetate, in gynecological treatments without reporting new clinical results.

This study found that treatment with cyproterone acetate was generally successful for women with virilizing features, showing improved results in younger women and those with adrenal hirsutism, despite some side effects.

Ethinylestradiol/Chlormadinone Acetate is a safe and effective birth control pill that also helps regulate menstrual cycles, reduces period pain, and treats certain skin and hair conditions.

The Journal für Ästhetische Chirurgie expanded its board to improve collaboration and knowledge in aesthetic surgery.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

This review discusses therapeutic principles for managing hirsutism and androgenetic alopecia during the menopausal transition and peri-/postmenopause but reports no new clinical results.

This report describes a sudden hair matting incident after shampooing a hairpiece and suggests that weathered hairs might explain this unusual event.

This study reports that hair growth and shedding in healthy women show annual seasonal patterns, with the highest shedding in summer and a less pronounced peak in spring.

This review discusses the effects and selection criteria of different progestogens in various treatments but reports no direct clinical comparisons of their metabolic effects.

This study found that treatment with cyproterone acetate and ethinylestradiol in hirsute women reduced testosterone and androstenedione levels, decreased hair growth, and increased cortisol levels without changing catecholamine excretion.

The document concludes that pediatricians play a vital role in supporting adolescents through puberty and should enhance their competence in this area.

This article reviews the discovery and various physiological effects of cyproterone acetate, reporting its established indications for several androgen-driven conditions but providing no new clinical data.

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

This publication discusses the political rationale behind the French regulator ANSM's decision to withdraw Diane®-35 from the market, in response to health concerns associated with third-generation oral contraceptives.

Two women experienced temporary hair loss and other side effects from imiquimod treatment for cervical issues, which stopped after ending the treatment.

The document concludes that treatments for female hair loss and excess body hair are available, but managing expectations is important.